The 2016 Career Development Award has been launched
The call for the 2016 Career Development Award of the Giovanni Armenise Harvard Foundation is online.
The program is designed to foster the development of outstanding, early-career scientists currently working abroad so that they may fulfill their potential and make significant contributions to their field of research in Italy. The Award provides $200,000 per year, for 3-5 years, to young scientists to establish their own lab at a host institute in which they can conduct independent research in the biological sciences. The funds cover the salaries of the awardee and of the other researchers in the lab, as well as the lab0’s technical equipment.
The deadline for the application is 22 July 2016
Approfondiamo le Biotecnologie
Corso di aggiornamento/formazione per insegnanti di Scienze Naturali e Chimica di scuole secondarie di primo e secondo grado a cura di ANISN sezione di Pavia. Sesto incontro.
CRISPR-Cas: correggere i difetti genetici e manipolare i genomi diventa realtà?
Proff. Luca Ferretti e Edda De Rossi
Sesto incontro: 19 aprile 2016 alle ore 15:30 – 18:00
DIPARTIMENTO DI BIOLOGIA E BIOTECNOLOGIE ¨LAZZARO SPALLANZANI”- Università di Pavia
The Candiolo Cancer Institute-IRCCS (Institute for Cancer Research and Treatment) is a private non-profit institute situated near Torino (http://www.ircc.it/irccit/?q=IRCC). The core of the Institute is at the interface between molecular biology and precision medicine. The new Jumping Genes Lab (http://www.ircc.it/irccit/?q=Jumping-Genes-Lab) is now recruiting an outstanding, creative Postdoctoral Fellow with expertise in CRISPR/Cas9 genetic engineering to cut out retrotransposon (jumping gene) insertions from human cell lines.
The laboratory investigates the impact of various retroelements on cancer, including LINE-1 retrotransposons (L1s). The Postdoctoral Fellow would perform various functional genetic assays on transposons. A major goal is to determine whether these elements can cause cancer and how frequently they are involved in tumorigenesis. To this end, the successful applicant will seamlessly remove and then re-insert putative cancer-driver L1 insertions from patient-derived cell lines and will monitor the phenotype of the cells. The fellow will also have the possibility to analyze somatic retrotransposon insertions in human tumors and plasma. To this end, prior work with human tissues can be an advantage. However, the only requirement is experience with CRISPR technology and cell culturing. Experience with genetic engineering methods other than CRISPR is also considered. Prior work with mobile elements is a plus, but not required. Excellent English communication skills are necessary. IRCCS provides cutting-edge equipment and core facilities. Applications including a European style CV and a summary of past accomplishments should be sent to email@example.com.
Ewing AD, Gacita A, Wood LD, Ma F, Xing D, Kim MS, Manda SS, Abril G, Pereira G, Makohon-Moore A, Looijenga LHJ, Gillis AJM, Hruban RH, Anders RA, Romans KE, Pandey A, Iacobuzio-Donahue CA, Vogelstein B, Kinzler KW, Kazazian HH Jr, Solyom S: Widespread somatic L1 retrotransposition occurs early during gastrointestinal cancer evolution. Genome Res. 2015 Aug, pii: gr.196238.115.
Solyom S*, Ewing AD*, Rahrmann EP, Doucet D, Nelson HH, Burns MB, Harris RS, Sigmon DF, Casella A, Erlanger B, Wheelan S, Upton KR, Shukla R, Faulkner GJ, Largaespada DA, and Kazazian HH Jr: Extensive somatic L1 retrotransposition in colorectal tumors. Genome Res. 2012 Dec;22(12):2328-2338. *equal contribution
Solyom S and Kazazian HH Jr: Mobile elements in the human genome: implications for disease. Genome Medicine 2012 Feb;4(2):12.
Solyom S*, Ewing AD*, Hancks DC*, Takeshima Y, Awano H, Matsuo M, Kazazian HH Jr: Pathogenic orphan transduction created by a non-reference LINE-1 retrotransposon. Hum Mutat. 2012 Feb;33(2):369-371. *equal contribution